Cepeda Ivan L, Flores Joseph, Cornfeldt Michael L, O'Kusky John R, Doudet Doris J
Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada.
J Neuropathol Exp Neurol. 2007 Jul;66(7):576-84. doi: 10.1097/nen.0b013e318093e521.
Intrastriatal transplantation of gelatin microcarrier-attached human retinal pigment epithelial cells (hRPE-GM) may represent an alternative source for cell therapy in Parkinson disease (PD). The use of human retinal pigment epithelial (hRPE) cells in PD relies on the capacity of these cells to produce l-dopa as an intermediate product in the eumelanin synthesis pathway. We investigated the behavioral effects of hRPE-GM implants on forelimb use asymmetries and hindlimb motor deficits in unilateral and bilateral 6-hydroxydopamine (6-OHDA) rat models of PD. We report that intrastriatal unilateral implantation of hRPE-GM in rats with 6-OHDA nigrostriatal lesions produce an amelioration of the contralateral forelimb disuse and the contralateral hindlimb deficits. These results further support the possibility that implantation of cultured hRPE cells may be a promising therapeutic option for patients with PD.
明胶微载体附着的人视网膜色素上皮细胞（hRPE-GM）的纹状体内移植可能是帕金森病（PD）细胞治疗的另一种细胞来源。在PD中使用人视网膜色素上皮（hRPE）细胞依赖于这些细胞在真黑素合成途径中产生左旋多巴作为中间产物的能力。我们研究了hRPE-GM植入对单侧和双侧6-羟基多巴胺（6-OHDA）大鼠PD模型前肢使用不对称和后肢运动缺陷的行为影响。我们报告，在具有6-OHDA黑质纹状体损伤的大鼠中纹状体内单侧植入hRPE-GM可改善对侧前肢废用和对侧后肢缺陷。这些结果进一步支持了植入培养的hRPE细胞可能是PD患者有前景的治疗选择的可能性。
